Estudios clínicos

WORK WITH US

Cell Genes Company has developed its proprietary mesenchymal stem cell expanding technology to provide effective, easy to use and standard stem cell and biologic products without any need to genetic matching around the world. All of our product must pass advanced regulatory parameters.

FURTHER INFORMATION

Don’t see an open position that interests you? Tell us
how you can help make a difference at Cell-Gene company.

As our company moves forward, we will consider our products usage for incurable conditions such as ARDS due to COVID-19, burn & diabetic wound, Crohn’s fistula, IBD, stroke, myocardial infarction, spinal cord injury and other unmet medical needs.

Indication

Product Candidate

preclinical

Phase I

Phase II

Phase III

Approval

ARDS due to COVID-19

CytoStem hUC

Burn Wound

CytoStem hAD

Diabetic Wound

CytoStem hAD CytoStem hUD

Bone Defect Regeneration

CytoStem hAD CytoStem hUD

Skin Substitute

CytoStem hAD CytoStem hUD

Osteoarthritis

CytoStem hAD

Crohn’s Fistula

CytoStem hAD

IBD

CytoStem hAD

Hi
Here you can see some frequently asked questions or contact us!

What passage are your cells?

Our human mesenchymal stem/stromal cells (hMSCs) are provided at a population doubling level (PDL) of 8-10 post-mononuclear isolation (Bone Marrow; Equivalent Passage 2) or 14-18 post-isolation from the perivascular region of Wharton’s Jelly (Umbilical Cord; Equivalent Passage 3). Due to variabilities of seeding and harvest densities we characterize our MSC “True Age” in terms of their PDL.

How often should I feed your cells?

A: There is no need to feed cells between passages. Our media is engineered to be a batch culture media, where no media exchange or feed is necessary when following our suggested protocols.

Are your vials sold from pooled donors?

No, we do not pool donors at any time during our production. Master Cell Banks (MCBs) are created from each donor source. Working Cell Banks (WCBs) are produced from our MCBs for general product sales.

What characterization do you provide for your hMSCs?

We characterize our hMSCs by following ISCT criteria: cell identity (surface marker expression), functional potency (angiogenic cytokine and IDO secretion), and trilineage differentiation (adipo-, osteo-, and chondrogenesis). This information is provided to allow customers to choose the optimal hMSC tissue type and donor for their specific application or target indication.